Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MDCX with free AI briefings, catalyst countdowns, and dilution alerts.

MDCX · Medicus Pharma Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5M Cash on Hand
1.3mo Cash Runway
Follow MDCX by email Get an email when MDCX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MDCX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

💰 Cash Runway & Dilution Risk

MDCX holds $5M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.5M/quarter from operations, an estimated runway of 1.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MDCX files for a raise →

👥 Who Owns MDCX

Insiders 100% Institutions (28 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Raza Bokhari
Chief Executive Officer, Director · +1.33M options
Insider 2,941,176 152.96% 2026-09-04
Carolyn F. Bonner
President and CFO · +600,000 options
Insider 1,489,493 77.46% 2026-09-04
Faisal Mehmud
Chief Medical Officer · +700,000 options
Insider 1,470,588 76.48% 2026-09-04
Andrew Alasdair Smith
Chief Operating Officer · +425,000 options
Insider 735,458 38.25% 2026-09-04
Edward J. Brennan
Chief Scientific Officer · +150,000 options
Insider 674,735 35.09% 2026-09-04

Share count 1,922,837 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MDCX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MDCX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.